Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 29, 2014, Pages

  Galan, Jacob A ^a,b   Geraghty, Kathryn M ^c   Lavoie, Geneviève ^a   Kanshin, Evgeny ^a,b   Tcherkezian, Joseph ^a,b   Calabrese, Viviane ^a,b   Jeschke, Grace R ^d   Turk, Benjamin E ^d   Ballif, Bryan A ^e   Blenis, John ^c   Thibault, Pierre ^a,b   Roux, Philippe P ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; P90 RIBOSOMAL S6 KINASE; PROGRAMMED CELL DEATH PROTEIN 4; PROTEIN 14 3 3; SERINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

14-3-3 PROTEINS; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; APOPTOSIS REGULATORY PROTEINS; CELL LINE; CELL NUCLEUS; CONSENSUS SEQUENCE; HUMANS; MELANOMA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PHOSPHOPROTEINS; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEOLYSIS; PROTEOME; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA-BINDING PROTEINS; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEINS;

EID: 84904671815     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405601111     Document Type: Article

References (32)

1. Meloche S, Pouysségur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26(22):3227-3239. (Pubitemid 46763017)
2. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7(4):295-308. (Pubitemid 46480970)
3. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27(7):877-895. (Pubitemid 351225383)
4. Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20(2):183-189. (Pubitemid 351317406)
5. Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75(1):50-83.
6. Romeo Y, Zhang X, Roux PP (2012) Regulation and function of the RSK family of protein kinases. Biochem J 441(2):553-569.
7. Smith JA, et al. (2005) Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 65(3):1027-1034. (Pubitemid 40216465)
8. Clark DE, et al. (2005) The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 65(8):3108-3116. (Pubitemid 40524591)
9. Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34(1):115-131.
10. Romeo Y, et al. (2013) RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene 32(24):2917-2926.
11. Zhao J, Meyerkord CL, Du Y, Khuri FR, Fu H (2011) 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol 22(7):705-712.
12. Gardino AK, Yaffe MB (2011) 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 22(7):688-695.
13. Moritz A, et al. (2010) Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 3(136):ra64.
14. Leighton IA, Dalby KN, Caudwell FB, Cohen PT, Cohen P (1995) Comparison of the specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 S6 kinase: The N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation. FEBS Lett 375(3):289-293.
15. Chen C, Turk BE (2010) Analysis of serine-threonine kinase specificity using arrayed positional scanning peptide libraries. Curr Protoc Mol Biol Chap 18:Unit 18.14.
16. Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31(13):3635-3641. (Pubitemid 37442212)
17. Dorrello NV, et al. (2006) S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314(5798):467-471. (Pubitemid 44628968)
18. Palamarchuk A, et al. (2005) Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 65(24):11282-11286. (Pubitemid 41821683)
19. Brunet A, et al. (2002) 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 156(5):817-828. (Pubitemid 34839865)
20. Masters SC, Fu H (2001) 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem 276(48):45193-45200.
21. Saha M, et al. (2012) RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. Biochem J 447(1):159-166.
22. Lankat-Buttgereit B, Göke R (2009) The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell 101(6):309-317.
23. Suzuki C, et al. (2008) PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. Proc Natl Acad Sci USA 105(9):3274-3279. (Pubitemid 351723543)
24. Roux PP, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282(19):14056-14064. (Pubitemid 47100467)
25. Schmid T, et al. (2008) Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res 68(5):1254-1260. (Pubitemid 351346830)
26. Blees JS, et al. (2010) Development of a high-throughput cell-based reporter assay to identify stabilizers of tumor suppressor Pdcd4. J Biomol Screen 15(1):21-29.
27. Romeo Y, Roux PP (2011) Paving the way for targeting RSK in cancer. Expert Opin Ther Targets 15(1):5-9.
28. Carriere A, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286(1):567-577.
29. Ballif BA, Cao Z, Schwartz D, Carraway KL, 3rd, Gygi SP (2006) Identification of 14-3-3epsilon substrates from embryonic murine brain. J Proteome Res 5(9):2372-2379. (Pubitemid 44330830)
30. Yaffe MB, et al. (1997) The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91(7):961-971. (Pubitemid 28027829)
31. Mok J, et al. (2010) Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs. Sci Signal 3(109):ra12.
32. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101(37):13489-13494. (Pubitemid 39238430)